Global Contact Dermatitis Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Contact Dermatitis treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Brickell Biotech Inc, Edesa Biotech Inc, Hapten Sciences Inc, ILiAD Biotechnologies LLC, NeuroCycle Therapeutics and others.
A Significant contribution to the Contact Dermatitis pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Contact Dermatitis pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Contact Dermatitis condition and increased access to investments is encouraging growth of Contact Dermatitis drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Contact Dermatitis drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Contact Dermatitis therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Contact Dermatitis pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Contact Dermatitis. Further, orphan drug status, fast track designation, grants awarded and other special status for Contact Dermatitis pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Contact Dermatitis pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Contact Dermatitis Pipeline candidates-
A Significant contribution to the Contact Dermatitis pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Contact Dermatitis pipeline included 6 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Contact Dermatitis condition and increased access to investments is encouraging growth of Contact Dermatitis drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Contact Dermatitis drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Contact Dermatitis therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Contact Dermatitis pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Contact Dermatitis. Further, orphan drug status, fast track designation, grants awarded and other special status for Contact Dermatitis pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Contact Dermatitis pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Contact Dermatitis Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Contact Dermatitis drugs
- Late phase: Phase 3 and in-approval Contact Dermatitis drugs
- Company overview
- Snapshot
- Contact Dermatitis therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Contact Dermatitis- Disease Overview
2.2 Contact Dermatitis- Pipeline Snapshot
2.3 Contact Dermatitis- Pipeline Drugs by Phase
2.4 Contact Dermatitis- Pipeline Drugs by Company
2.5 Contact Dermatitis- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Brickell Biotech Inc Contact Dermatitis Drug Pipeline, H2- 2019
3.2 Edesa Biotech Inc Contact Dermatitis Drug Pipeline, H2- 2019
3.3 Hapten Sciences Inc Contact Dermatitis Drug Pipeline, H2- 2019
3.4 ILiAD Biotechnologies LLC Contact Dermatitis Drug Pipeline, H2- 2019
3.5 NeuroCycle Therapeutics Contact Dermatitis Drug Pipeline, H2- 2019
3.6 Signum Dermalogix Inc Contact Dermatitis Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Contact Dermatitis- Phase 1 Drug Details
4.2 Contact Dermatitis- Phase 1 Drug Overview
4.3 Contact Dermatitis- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Contact Dermatitis- Phase 2 Drug Details
5.2 Contact Dermatitis- Phase 2 Drug Overview
5.3 Contact Dermatitis- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Contact Dermatitis- Phase 3 Drug Details
6.2 Contact Dermatitis- Phase 3 Drug Overview
6.3 Contact Dermatitis- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Contact Dermatitis- Pre-clinical Phase Drug Details
7.2 Contact Dermatitis- Pre-clinical Phase Drug Overview
7.3 Contact Dermatitis- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Contact Dermatitis- Disease Overview
2.2 Contact Dermatitis- Pipeline Snapshot
2.3 Contact Dermatitis- Pipeline Drugs by Phase
2.4 Contact Dermatitis- Pipeline Drugs by Company
2.5 Contact Dermatitis- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Brickell Biotech Inc Contact Dermatitis Drug Pipeline, H2- 2019
3.2 Edesa Biotech Inc Contact Dermatitis Drug Pipeline, H2- 2019
3.3 Hapten Sciences Inc Contact Dermatitis Drug Pipeline, H2- 2019
3.4 ILiAD Biotechnologies LLC Contact Dermatitis Drug Pipeline, H2- 2019
3.5 NeuroCycle Therapeutics Contact Dermatitis Drug Pipeline, H2- 2019
3.6 Signum Dermalogix Inc Contact Dermatitis Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Contact Dermatitis- Phase 1 Drug Details
4.2 Contact Dermatitis- Phase 1 Drug Overview
4.3 Contact Dermatitis- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Contact Dermatitis- Phase 2 Drug Details
5.2 Contact Dermatitis- Phase 2 Drug Overview
5.3 Contact Dermatitis- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Contact Dermatitis- Phase 3 Drug Details
6.2 Contact Dermatitis- Phase 3 Drug Overview
6.3 Contact Dermatitis- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Contact Dermatitis- Pre-clinical Phase Drug Details
7.2 Contact Dermatitis- Pre-clinical Phase Drug Overview
7.3 Contact Dermatitis- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
